Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer
dc.contributor.author | Ölmez, Fatma | |
dc.contributor.buuauthor | Çubukçu, Erdem | |
dc.contributor.buuauthor | Kanat, Özkan | |
dc.contributor.buuauthor | Ölmez, Ömer Fatih | |
dc.contributor.buuauthor | Kabul, Selva | |
dc.contributor.buuauthor | Canhoroz, Mustafa | |
dc.contributor.buuauthor | Avcı, Nilüfer | |
dc.contributor.buuauthor | Deligönül, Adem | |
dc.contributor.buuauthor | Hartavi, Mustafa | |
dc.contributor.buuauthor | Çubukçu, Sinem | |
dc.contributor.buuauthor | Kurt, Ender | |
dc.contributor.buuauthor | Evrensel, Türkkan | |
dc.contributor.buuauthor | Gökgöz, Şehsuvar | |
dc.contributor.buuauthor | Manavoǧlu, Osman | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-9732-5340 | tr_TR |
dc.contributor.researcherid | AAJ-1027-2021 | tr_TR |
dc.contributor.researcherid | DJG-4827-2022 | tr_TR |
dc.contributor.researcherid | ETP-1691-2022 | tr_TR |
dc.contributor.researcherid | CYM-0930-2022 | tr_TR |
dc.contributor.researcherid | CAH-9737-2022 | tr_TR |
dc.contributor.researcherid | CJW-6018-2022 | tr_TR |
dc.contributor.researcherid | CCT-7946-2022 | tr_TR |
dc.contributor.researcherid | ESM-4544-2022 | tr_TR |
dc.contributor.researcherid | CUI-5353-2022 | tr_TR |
dc.contributor.researcherid | CMF-4464-2022 | tr_TR |
dc.contributor.researcherid | DAS-3088-2022 | tr_TR |
dc.contributor.researcherid | EXK-4525-2022 | tr_TR |
dc.contributor.researcherid | FLP-9613-2022 | tr_TR |
dc.contributor.scopusid | 53986153800 | tr_TR |
dc.contributor.scopusid | 55881548500 | tr_TR |
dc.contributor.scopusid | 55779185600 | tr_TR |
dc.contributor.scopusid | 56113027300 | tr_TR |
dc.contributor.scopusid | 52663246200 | tr_TR |
dc.contributor.scopusid | 55390409800 | tr_TR |
dc.contributor.scopusid | 37088030300 | tr_TR |
dc.contributor.scopusid | 55370753300 | tr_TR |
dc.contributor.scopusid | 55778484600 | tr_TR |
dc.contributor.scopusid | 7006207332 | tr_TR |
dc.contributor.scopusid | 6603942124 | tr_TR |
dc.contributor.scopusid | 6603238737 | tr_TR |
dc.contributor.scopusid | 6602587152 | tr_TR |
dc.date.accessioned | 2024-01-29T07:44:49Z | |
dc.date.available | 2024-01-29T07:44:49Z | |
dc.date.issued | 2013-01-29 | |
dc.description.abstract | Purpose: To determine the prognostic significance of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, Ki-67, and nm23 immunohistochemical expression with respect to progression free survival (PFS) and overall survival (OS) in Turkish patients with invasive breast cancer (IBC). Methods: Patients with IBC (n = 81; mean age = 51.9 ± 11.1 years) were prospectively enrolled at the Department of Oncology, Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections. Results: We did not find any significant association between immunohistochemical expression of ER, PR, HER2/neu, Ki-67, and nm23 and the baseline characteristics of IBC patients. The median patient PFS was 30 months (range 22-45), and the median OS was 32 months (range 23-46). Stratification of the patient population according to nm23 immunohistochemical expression revealed a statistically significant difference in terms of both OS (p < 0.05) and DFS (p < 0.05). Multivariate Cox regression analysis indicated that tumor grade, axillary lymph node status, and nm23 immunohistochemical expression were the 3 main independent prognostic factors for PFS and OS in IBC patients. Conclusion: Reduced nm23 immunohistochemical expression is an independent negative prognostic factor for OS and PFS. Patients with negative nm23 expression may require a more intensive follow-up. | en_US |
dc.identifier.citation | Çubukçu, E. vd. (2013). ''Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer''. Journal of B.U.ON., 18(2), 359-365. | en_US |
dc.identifier.eissn | 2241-6293 | |
dc.identifier.endpage | 365 | tr_TR |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issue | 2 | tr_TR |
dc.identifier.pubmed | 23818346 | tr_TR |
dc.identifier.scopus | 2-s2.0-84879574962 | tr_TR |
dc.identifier.startpage | 359 | tr_TR |
dc.identifier.uri | https://www.jbuon.com/archive/18-2-359.pdf | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/39354 | |
dc.identifier.volume | 18 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Imprimatur Publications | en_US |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Journal of B.U.ON. | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | tr_TR |
dc.subject | Oncology | en_US |
dc.subject | Immunohistochemistry | en_US |
dc.subject | Invasive breast cancer | en_US |
dc.subject | Nm23 | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Survival | en_US |
dc.subject | Lymph-node metastasis | en_US |
dc.subject | Hormone-receptor | en_US |
dc.subject | In-situ | en_US |
dc.subject | Carcinoma | en_US |
dc.subject | Suppressor | en_US |
dc.subject | Biology | en_US |
dc.subject | Protein | en_US |
dc.subject.emtree | Epidermal growth factor receptor 2 | en_US |
dc.subject.emtree | Estrogen receptor | en_US |
dc.subject.emtree | Ki 67 antigen | en_US |
dc.subject.emtree | Nucleoside diphosphate kinase NM23 | en_US |
dc.subject.emtree | Progesterone receptor | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Breast cancer | en_US |
dc.subject.emtree | Cancer patient | en_US |
dc.subject.emtree | Cancer prognosis | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human tissue | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Overall survival | en_US |
dc.subject.emtree | Progression free survival | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Tissue section | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Breast neoplasms | en_US |
dc.subject.mesh | Carcinoma | en_US |
dc.subject.mesh | Disease-free survival | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunohistochemistry | en_US |
dc.subject.mesh | Kaplan-meier estimate | en_US |
dc.subject.mesh | Ki-67 antigen | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Multivariate analysis | en_US |
dc.subject.mesh | Neoplasm invasiveness | en_US |
dc.subject.mesh | NM23 nucleoside diphosphate kinases | en_US |
dc.subject.mesh | Predictive value of tests | en_US |
dc.subject.mesh | Proportional hazards models | en_US |
dc.subject.mesh | Prospective studies | en_US |
dc.subject.mesh | Receptor, erbB-2 | en_US |
dc.subject.mesh | Receptors, estrogen | en_US |
dc.subject.mesh | Receptors, progesterone | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Turkey | en_US |
dc.subject.scopus | Nucleoside-Diphosphate Kinase; Metastasis; Prunes | en_US |
dc.subject.wos | Oncology | en_US |
dc.title | Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q4 (Oncology) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: